Bioaffinity Technologies, INC 10-Q quarterly reports

bioAffinity Technologies reports increased revenue for its CyPath Lung diagnostic test but faces substantial doubt about its going concern status and a Nasdaq delisting warning.

BioAffinity Technologies reported a widened net loss of $5.1 million in Q3 2025, despite an 86% increase in CyPath Lung revenue, as it navigates strategic shifts and capital raises.

BioAffinity Technologies reports increased net losses and significant liquidity challenges, raising substantial doubt about its ability to continue as a going concern, despite growth in its CyPath Lung diagnostic test revenue and new patent grants.

bioAffinity Technologies' Q1 2025 revenue decreased by 23% due to strategic actions, but CyPath Lung testing revenue increased significantly.

bioAffinity Technologies saw a significant increase in revenue in Q3 2024, primarily due to the acquisition of a clinical pathology lab, but continues to operate at a loss and faces substantial doubt about its ability to continue as a going concern.

bioAffinity Technologies reports a net loss of $2.1 million for Q2 2024, with significant revenue growth driven by the acquisition of Precision Pathology Laboratory Services.

bioAffinity Technologies' first quarter 2024 results show a significant increase in revenue due to the acquisition of Precision Pathology Laboratory Services, but the company continues to operate at a loss.